Winshine Science Co (HKSE:00209) Cash And Cash Equivalents : HK$119.3 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Winshine Science Co Cash And Cash Equivalents?

Winshine Science Co's quarterly cash and cash equivalents declined from Dec. 2022 (HK$49.77 Mil) to Jun. 2023 (HK$38.79 Mil) but then increased from Jun. 2023 (HK$38.79 Mil) to Dec. 2023 (HK$119.34 Mil).

Winshine Science Co's annual cash and cash equivalents declined from Dec. 2021 (HK$66.63 Mil) to Dec. 2022 (HK$49.77 Mil) but then increased from Dec. 2022 (HK$49.77 Mil) to Dec. 2023 (HK$119.34 Mil).

Winshine Science Co Cash And Cash Equivalents Historical Data

The historical data trend for Winshine Science Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winshine Science Co Cash And Cash Equivalents Chart

Winshine Science Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

89.28

56.14

66.63

49.77

119.34

Winshine Science Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															66.63	48.06	49.77	38.79	119.34

Winshine Science Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Winshine Science Co (HKSE:00209) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Winshine Science Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Winshine Science Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Winshine Science Co (HKSE:00209) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Travel & Leisure » Winshine Science Co Ltd (HKSE:00209) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

287-299 Queen's Road, Room 1002, 10th Floor, 299 QRC, Central, Hong Kong, HKG

Website

http://www.winshine.com

Winshine Science Co Ltd is an investment holding company. The company's segment includes Securities investments, Toys, and Medical & health. It generates maximum revenue from the Toys segment. The toys segment derives its revenue from manufacturing for the sale of toys. The securities investments segment derives its profits or losses from dividends received from, and other gains or losses from, equity securities investments. The medical and health segment is under the development stage in which research and development expenses for medical and health technology development have been incurred. Its geographical segments are Hong Kong, China, the United States, Europe, and Korea, of which the majority of its revenue comes from the United States.

Executives

Wang Honggang	2101 Beneficial owner
U Credit (hk) Limited	2106 Person having a security interest in shares
Csc Holdings Limited	2106 Person having a security interest in shares
Hurray Talent Investment Development Limited	2101 Beneficial owner
Li Zhonghai	2201 Interest of corporation controlled by you
Liu Lian	2201 Interest of corporation controlled by you
Richsun Investment Development Limited	2101 Beneficial owner
Hong Kong Huiheng Trading And Investment Co., Limited	2101 Beneficial owner
Jiang Qinghui	2201 Interest of corporation controlled by you
Csc Holdings Limited (formerly Known As "china Strategic Holdings Limited")	2106 Person having a security interest in shares
China Strategic Holdings Limited	2106 Person having a security interest in shares
Shen Jia	2101 Beneficial owner

Winshine Science Co (HKSE:00209) Headlines

No Headlines